Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 4, 2012, Pages 721-725

  Sharon, Elad ^a   Zhang, Jingli ^a   Hollevoet, Kevin ^a   Steinberg, Seth M ^a   Pastan, Ira ^a   Onda, Masanori ^a   Gaedcke, Jochen ^b   Ghadimi, B Michael ^b   Ried, Thomas ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

biliary cancer; megakaryocyte potentiating factor; mesothelin; pancreatic cancer

Indexed keywords

BIOLOGICAL MARKER; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PRIORITY JOURNAL;

ADULT; BILIARY TRACT NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860432624     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.816     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Payne SJ, Stebbing J, Wilson P, Slater S. Outcomes in unresectable and locally advanced resected cholangiocarcinoma. Expert Rev Anticancer Ther 2011;11:705-9.
3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-20.
4. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
5. Szajda SD, Waszkiewicz N, Chojnowska S, Zwierz K. Carbohydrate markers of pancreatic cancer. Biochem Soc Trans 2011;39:340-3.
6. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
7. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27. (Pubitemid 46631379)
8. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53. (Pubitemid 43166134)
9. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6. (Pubitemid 37443528)
10. Hollevoet K, Nackaerts K, Thimpont J, GermonpréP, Bosquée L, De Vuyst P, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-5.
11. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12:4225-31.
12. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42. (Pubitemid 38812466)
13. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20. (Pubitemid 43823532)
14. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identifi cation of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8. (Pubitemid 34044602)
15. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45. (Pubitemid 41740183)
16. Johnston FM, Tan MC, Tan BR Jr., Porembka MR, Brunt EM, Linehan DC, et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009;15:6511-8.
17. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, editors. American Joint Committee on Cancer (AJCC) cancer staging manual. 6th ed. New York, NY: Springer, 2002.
18. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666-72. (Pubitemid 46580236)
19. Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008;62:45-54.
20. Hollevoet K, Nackaerts K, Thas O, Thimpont J, GermonpréP, De Vuyst P, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest Epub 2011 Jul 7. PMID: 21737491.
21. Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 2011;40:1276-82.
22. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011;17:1181-9.
23. Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquée L, De Vuyst P, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol 2011;6:1930-7.
24. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239-46. (Pubitemid 47620999)
25. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T. Clinical signifi cance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011;49:1721-6.